Pharmaceuticals News

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the...

REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease...

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...

CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent...